Mac-2 binding protein glycosylation isomer as a marker of hepatocellular carcinoma in patients with hepatitis C virus
Hanafy, A., Muftah, K., Mohammad, F., Ibrahim, A. (2023). Mac-2 binding protein glycosylation isomer as a marker of hepatocellular carcinoma in patients with hepatitis C virus. EKB Journal Management System, (), -. doi: 10.21608/zumj.2023.239579.2924
Amr Shaaban Hanafy; Khalid Ali Muftah; Fedaa Nabil Mohammad; Amr Samir Ibrahim. "Mac-2 binding protein glycosylation isomer as a marker of hepatocellular carcinoma in patients with hepatitis C virus". EKB Journal Management System, , , 2023, -. doi: 10.21608/zumj.2023.239579.2924
Hanafy, A., Muftah, K., Mohammad, F., Ibrahim, A. (2023). 'Mac-2 binding protein glycosylation isomer as a marker of hepatocellular carcinoma in patients with hepatitis C virus', EKB Journal Management System, (), pp. -. doi: 10.21608/zumj.2023.239579.2924
Hanafy, A., Muftah, K., Mohammad, F., Ibrahim, A. Mac-2 binding protein glycosylation isomer as a marker of hepatocellular carcinoma in patients with hepatitis C virus. EKB Journal Management System, 2023; (): -. doi: 10.21608/zumj.2023.239579.2924

Mac-2 binding protein glycosylation isomer as a marker of hepatocellular carcinoma in patients with hepatitis C virus

Zagazig University Medical Journal
Articles in Press, Accepted Manuscript, Available Online from 08 October 2023  XML
Document Type: Review Articles
DOI: 10.21608/zumj.2023.239579.2924
View on SCiNiTO View on SCiNiTO
Authors
Amr Shaaban Hanafy1; Khalid Ali Muftah email 2; Fedaa Nabil Mohammad3; Amr Samir Ibrahim1
1Internal Medicine Department, Faculty of Medicine, Zagazig University
2M.B.B.CH - Libya Faculty of Medicine, sirt University
3Medical Microbiology and Immunology Department, Faculty of Medicine, Zagazig University
Abstract
Background: In chronic liver disorders, a precise Evaluation of hepatic fibrosis is essential from a medical perspective. The glycosylation isomer of Mac-2 binding protein (M2BPGi) is a novel blood marker for liver fibrosis. M2BPGi is able to predict the development and prognosis of hepatocellular carcinoma (HCC) in addition to hepatic fibrosis in individuals with long-term liver diseases, such as persistent hepatitis C virus (HCV). In patients with cirrhosis, M2BPGi can also be utilized to assess liver function and prognosis. The etiology and the presence or lack of treatment affect M2BPGi levels. Consequently, the background and treatment status must be taken into account while establishing the M2BPGi threshold for the diagnosis of hepatic fibrosis and the prediction of the development of HCC.

Aim: to assess the value of the glycosylation isomer of Mac-2 binding protein as a predictor of hepatocellular carcinoma in hepatitis C virus patients.

Conclusion: In the HCV cohort, M2BPGi can be utilized to predict HCC. evaluating M2BPGi as a biomarker for HCC in a wider range of patient populations—including those with severe hepatic fibrosis burdens and a wider range of liver diseases—more research is required.
Keywords
M2BPGi; HCC; Cirrhosis
Statistics
Article View: 58